Welcome to our dedicated page for Royalty Pharma Plc SEC filings (Ticker: RPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Royalty Pharma plc filings document the company’s biopharmaceutical royalty business, public equity structure, governance, financing activity, and material events. Form 8-K reports furnish quarterly and annual results, including Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, and developments affecting royalty and funding arrangements.
Regulation FD and material-agreement disclosures describe royalty transactions, synthetic royalty funding, senior secured loan arrangements, and portfolio-related clinical or regulatory events. Other filings cover Class A ordinary shares listed on Nasdaq, senior note issuances and related guarantees, annual meeting matters, board and compensation governance, shareholder voting items, and changes involving directors or officers.
Royalty Pharma plc reported strong growth for Q4 and full year 2025 and issued 2026 guidance. Portfolio Receipts rose 18% in Q4 2025 to $874 million and 16% for 2025 to $3,254 million, while Royalty Receipts grew 13% to $3,127 million, led by Voranigo, Trelegy, Tremfya and the cystic fibrosis franchise.
Adjusted EBITDA increased 16% to $2,966 million and Portfolio Cash Flow rose 11% to $2,724 million in 2025, though net cash from operating activities declined to $2,490 million from $2,769 million. The company deployed $2.6 billion on royalty transactions and repurchased 37 million shares for $1.2 billion, alongside $512 million of dividends, supported by $619 million of cash and $9.2 billion of debt at year-end.
For 2026, Royalty Pharma expects Portfolio Receipts of $3,275 million to $3,425 million, implying Royalty Receipts growth of 3% to 8%, with lower operating and professional costs as a percentage of Portfolio Receipts following the internalization of its external manager and interest paid projected at $350 million to $360 million.
Royalty Pharma plc EVP & CFO Terrance P. Coyne reported indirect sales of Class A Ordinary Shares through entities associated with him. Between February 2 and 4, 2026, TPC RP 2021, LLC and TPC RP EPA1 LLC sold multiple share blocks at weighted average prices around $42–$43 per share, with detailed price ranges disclosed in footnotes. All sales were made under a Rule 10b5-1 trading plan adopted on August 8, 2025. The filing also lists remaining indirect holdings in family vehicles and IRAs, direct holdings, and additional partnership and Class E interests exchangeable into Class A Ordinary Shares, with certain Class E shares subject to vesting conditions.
A shareholder in RPRX has filed a Form 144 notice to sell up to 135,117 shares of common stock through Goldman Sachs & Co. LLC, with an aggregate market value of $5,805,977.49. The notice lists 427,247,489 shares outstanding and targets an approximate sale date of February 3, 2026 on NASD.
The shares to be sold were acquired from the issuer in a private transaction on June 16, 2020 and as compensation via performance awards on February 12, 2020. The filing also details multiple past three‑month sales by entities TPC RP EPA1 LLC and TPC RP 2021 LLC, including individual transactions of up to 69,665 shares for $2,938,636.90 in gross proceeds.
RPRX filed a notice of proposed insider sales of common stock under Rule 144. The filing covers up to 108,424 common shares to be sold through Goldman Sachs & Co. LLC on the NASD, with an aggregate market value of $4,592,840.64 and 427,247,489 shares outstanding.
The seller reports acquiring 102,581 shares on 06/16/2020 from the issuer in a private transaction and 5,843 shares on 02/12/2020 as compensation through performance awards. The notice also lists multiple recent common stock sales over the past three months by TPC RP EPA1 LLC and TPC RP 2021 LLC, each generating six-figure gross proceeds.
Royalty Pharma plc executive Marshall Urist reported an automatic share sale under a pre-arranged trading plan. On January 30, 2026, an entity listed as Sandy Lamm LLC sold 20,000 Class A Ordinary Shares at a weighted average price of $41.0905 per share under a Rule 10b5-1 plan adopted on September 16, 2025.
After this sale, accounts associated with Urist continued to hold 19,020 Class A Ordinary Shares indirectly through an IRA and 7,398 Class A Ordinary Shares directly. The filing also notes additional exchangeable partnership and Class E ordinary share interests that could convert into Class A Ordinary Shares, subject to vesting conditions.
Royalty Pharma plc executive Marshall Urist, EVP of Research & Investments, reported a planned sale of Class A Ordinary Shares through an affiliated entity. On January 23, 2026, 20,000 Class A Ordinary Shares were sold by Sandy Lamm LLC, an entity associated with Urist, at a weighted average price of $40.2555 per share under a pre-established Rule 10b5-1 trading plan adopted on September 16, 2025.
Following this transaction, the filing shows indirect ownership of 20,000 shares through Sandy Lamm LLC, 19,020 shares held indirectly via an IRA, and 7,398 shares held directly. The filing also notes additional exchangeable interests and Class E Ordinary Shares in affiliated Royalty Pharma entities that can convert into Royalty Pharma plc Class A Ordinary Shares, with some of those Class E shares subject to vesting conditions.
Royalty Pharma plc EVP & CFO Terrance P. Coyne reported automatic sales of Class A Ordinary Shares through entities associated with him. On January 20, 2026, TPC RP 2021, LLC sold 65,832 Class A shares at a weighted average price of $39.3484 per share, leaving 394,996 shares held indirectly by that LLC. On the same date, TPC RP EPA1 LLC sold 3,750 Class A shares at a weighted average price of $39.3484, with 36,010 shares remaining held indirectly by that LLC.
All reported sales were made under a Rule 10b5-1 trading plan adopted by Coyne on August 8, 2025, meaning they were pre-arranged. In addition, Coyne reports indirect holdings of Class A shares through a spouse’s IRA, his own IRA, and shares held by his spouse, as well as limited partnership and Class E Ordinary Share interests that are exchangeable for additional Class A Ordinary Shares, with some of those interests subject to vesting conditions.
Royalty Pharma EVP Marshall Urist, through Sandy Lamm LLC, sold 20,000 Class A Ordinary Shares of Royalty Pharma plc on January 16, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on September 16, 2025. The shares were sold at a weighted average price of $39.5173 in multiple trades between $39.37 and $39.76 per share. Following the sale, Sandy Lamm LLC held 40,000 shares, an IRA associated with the reporting person held 19,020 shares, and 7,398 shares were held directly. In addition, the reporting person and family vehicles hold limited partnership and holding company interests exchangeable into 2,474,120 and 1,356,528 Class A Ordinary Shares, with certain Class E shares subject to vesting conditions.
A holder of the issuer’s common stock has filed a Form 144 notice to sell 69,582 shares of common stock through Goldman Sachs & Co. LLC, with an aggregate market value of $2,719,960.38. The filing notes that there were 427,247,489 shares of this class outstanding and that the approximate sale date is January 20, 2026 on the NASD.
The shares to be sold were originally acquired from the issuer in 2020, including 65,832 shares in a private transaction on June 16, 2020 and 3,750 shares as compensation performance awards on February 12, 2020. The notice also lists prior sales over the past three months by entities such as TPC RP 2021 LLC and TPC RP EPA1 LLC, including blocks of 32,916 shares of common stock on various dates, with single transactions generating gross proceeds such as $1,277,555.54.
Royalty Pharma plc reported an insider transaction involving an entity affiliated with its EVP, Research & Investments, Marshall Urist. On January 9, 2026, Sandy Lamm LLC, an entity associated with Urist, sold 20,000 Class A Ordinary Shares at a weighted average price of $40.7817 per share pursuant to a Rule 10b5-1 trading plan adopted on September 16, 2025. After this sale, 60,000 Class A Ordinary Shares were held indirectly through Sandy Lamm LLC, 19,020 shares were held indirectly through an IRA, and 7,398 shares were held directly.